Pre-order Enquiry
Request Free Sample
Healthcare
Aerospace & Defence
Agriculture
Automations
Chemicals & Advanced Materials
Food & Beverages
Information & Communication Technology
Oil & Gas
Power & Energy
About Graft vs Host Disease (GVHD) Treatment
Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.
Technavio’s analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bristol-Myers Squibb
• Novartis
• Pfizer
• F. Hoffmann-La Roche
Other prominent vendors
• Abbott
• AbbVie
• Allergan
• Anterogen
• Astellas Pharma
• Athersys
• Baxter
• Caladrius
• Cellular Biomedicine Group
• Cipla
• Eisai
• Eli Lilly
• GlaxoSmithKline
• Glenmark
• Helsinn Healthcare
• Heron Therapeutics
• Incyte Corporation
• IPCA Laboratories
• Kadmon Holdings
• Lupin
• Osiris Therapeutics
• RedHill
• Sanofi
• Shire
• Sun Pharmaceutical Industries
• Takeda Pharmaceutical
• ViaCyte
Market driver
• Increased prevalence of cancer
• For a full, detailed list, view our report
Market challenge
• Off-label use of drugs
• For a full, detailed list, view our report
Market trend
• Inorganic growth strategies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Graft-versus-host disease (GVHD) is an immune-mediated disease, which results from a multifaceted interaction amongst donor and recipient's adaptive immunity. GVHD is an induced indication and emerges post organ or tissue transplant. The probability of developing GVHD is higher in allogeneic transplant, a transplant where donor's organ/cell are used for transplantation compared with autologous transplant, a transplant where individual's cells have been used for transplant.
Technavio’s analysts forecast the global graft vs host disease (GVHD) treatment market to grow at a CAGR of 7.15% during the period 2017-2021.
Covered in this report
The report covers the present scenario and the growth prospects of the global graft vs host disease (GVHD) treatment market for 2017-2021. To calculate the market size, the report considers sales of branded, generic, and off-label drugs.
The market is divided into the following segments based on geography:
• Americas
• APAC
• EMEA
Technavio's report, Global Graft vs Host Disease (GVHD) Treatment Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors
• Bristol-Myers Squibb
• Novartis
• Pfizer
• F. Hoffmann-La Roche
Other prominent vendors
• Abbott
• AbbVie
• Allergan
• Anterogen
• Astellas Pharma
• Athersys
• Baxter
• Caladrius
• Cellular Biomedicine Group
• Cipla
• Eisai
• Eli Lilly
• GlaxoSmithKline
• Glenmark
• Helsinn Healthcare
• Heron Therapeutics
• Incyte Corporation
• IPCA Laboratories
• Kadmon Holdings
• Lupin
• Osiris Therapeutics
• RedHill
• Sanofi
• Shire
• Sun Pharmaceutical Industries
• Takeda Pharmaceutical
• ViaCyte
Market driver
• Increased prevalence of cancer
• For a full, detailed list, view our report
Market challenge
• Off-label use of drugs
• For a full, detailed list, view our report
Market trend
• Inorganic growth strategies
• For a full, detailed list, view our report
Key questions answered in this report
• What will the market size be in 2021 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
